Main demographics of the HIV-2 study population treated with integrase inhibitors
| Characteristic . | Total . | Antiretroviral- naive . | Treatment- experienced . |
|---|---|---|---|
| No. | 44 | 18 | 26 |
| Median age at diagnosis, years | 43 (37–50) | 44.5 (38–53) | 43 (34–49) |
| Gender, n (%) | |||
| male | 32 (72.7) | 10 | 22 |
| female | 12 (27.3) | 8 | 4 |
| Risk group, n (%) | |||
| heterosexual | 31 (70.5) | 13 | 18 |
| homosexual | 1 (2.3) | – | 1 |
| vertical | 1 (2.3) | – | 1 |
| unknown | 11 (25) | 5 | 6 |
| Origin, n (%) | |||
| Africa | 36 (81.8) | 14 | 22 |
| Spain | 5 (11.4) | 2 | 3 |
| Portugal | 2 (4.5) | 1 | 1 |
| Brazil | 1 (2.3) | 1 | – |
| Year of diagnosis, n (%) | |||
| <2014 | 32 (72.7) | 8 | 24 |
| ≥2014 | 12 (27.3) | 10 | 2 |
| HIV-1 coinfection, n (%) | 5 (11.4) | 3 | 2 |
| Characteristic . | Total . | Antiretroviral- naive . | Treatment- experienced . |
|---|---|---|---|
| No. | 44 | 18 | 26 |
| Median age at diagnosis, years | 43 (37–50) | 44.5 (38–53) | 43 (34–49) |
| Gender, n (%) | |||
| male | 32 (72.7) | 10 | 22 |
| female | 12 (27.3) | 8 | 4 |
| Risk group, n (%) | |||
| heterosexual | 31 (70.5) | 13 | 18 |
| homosexual | 1 (2.3) | – | 1 |
| vertical | 1 (2.3) | – | 1 |
| unknown | 11 (25) | 5 | 6 |
| Origin, n (%) | |||
| Africa | 36 (81.8) | 14 | 22 |
| Spain | 5 (11.4) | 2 | 3 |
| Portugal | 2 (4.5) | 1 | 1 |
| Brazil | 1 (2.3) | 1 | – |
| Year of diagnosis, n (%) | |||
| <2014 | 32 (72.7) | 8 | 24 |
| ≥2014 | 12 (27.3) | 10 | 2 |
| HIV-1 coinfection, n (%) | 5 (11.4) | 3 | 2 |
Main demographics of the HIV-2 study population treated with integrase inhibitors
| Characteristic . | Total . | Antiretroviral- naive . | Treatment- experienced . |
|---|---|---|---|
| No. | 44 | 18 | 26 |
| Median age at diagnosis, years | 43 (37–50) | 44.5 (38–53) | 43 (34–49) |
| Gender, n (%) | |||
| male | 32 (72.7) | 10 | 22 |
| female | 12 (27.3) | 8 | 4 |
| Risk group, n (%) | |||
| heterosexual | 31 (70.5) | 13 | 18 |
| homosexual | 1 (2.3) | – | 1 |
| vertical | 1 (2.3) | – | 1 |
| unknown | 11 (25) | 5 | 6 |
| Origin, n (%) | |||
| Africa | 36 (81.8) | 14 | 22 |
| Spain | 5 (11.4) | 2 | 3 |
| Portugal | 2 (4.5) | 1 | 1 |
| Brazil | 1 (2.3) | 1 | – |
| Year of diagnosis, n (%) | |||
| <2014 | 32 (72.7) | 8 | 24 |
| ≥2014 | 12 (27.3) | 10 | 2 |
| HIV-1 coinfection, n (%) | 5 (11.4) | 3 | 2 |
| Characteristic . | Total . | Antiretroviral- naive . | Treatment- experienced . |
|---|---|---|---|
| No. | 44 | 18 | 26 |
| Median age at diagnosis, years | 43 (37–50) | 44.5 (38–53) | 43 (34–49) |
| Gender, n (%) | |||
| male | 32 (72.7) | 10 | 22 |
| female | 12 (27.3) | 8 | 4 |
| Risk group, n (%) | |||
| heterosexual | 31 (70.5) | 13 | 18 |
| homosexual | 1 (2.3) | – | 1 |
| vertical | 1 (2.3) | – | 1 |
| unknown | 11 (25) | 5 | 6 |
| Origin, n (%) | |||
| Africa | 36 (81.8) | 14 | 22 |
| Spain | 5 (11.4) | 2 | 3 |
| Portugal | 2 (4.5) | 1 | 1 |
| Brazil | 1 (2.3) | 1 | – |
| Year of diagnosis, n (%) | |||
| <2014 | 32 (72.7) | 8 | 24 |
| ≥2014 | 12 (27.3) | 10 | 2 |
| HIV-1 coinfection, n (%) | 5 (11.4) | 3 | 2 |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
